Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II basket study of Debio 1347 in FGFR1/2/3 fusion-positive solid tumors
NL-OMON48084Phase 2Active, not recruiting
- Sponsor
- Debiopharm
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zoligratinib in Nonhematologic neoplasms, biliary cancer, transitional cell carcinoma (TCC) and 6 more (3 cohorts), sponsored by Debiopharm. Primary endpoint: Objective response rate. Started Feb 2019; status: active, not recruiting.
02
Drugs
zoligratinib
03
Conditions
Nonhematologic neoplasmsbiliary cancertransitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NL-OMON48084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48084.